<DOC>
	<DOCNO>NCT00997607</DOCNO>
	<brief_summary>This study test two new vaccine , one Ebola one Marburg virus , see safe , side effect , create immune response people receive .</brief_summary>
	<brief_title>Evaluating Ebola Marburg Vaccine Uganda</brief_title>
	<detailed_description>The Ebola Marburg viruses filovirus know induce hemorrhagic fever—a set symptom characterize sudden onset , ache , fever , bleed internal organ . Both filovirus associate high mortality rate , Centers Disease Control ( CDC ) list Category A bioterrorism agent potential major public health impact . Vaccines virus development use prime-boost strategy involve multiple injection period time confer long-lasting immunity . Preliminary research support vaccine ' safety . This study test experimental vaccine Ebola Marburg virus , first administer separately together , ensure safe side effect . Participation study entail 11 study visit 2 year . The study two part , complete sequentially , three group . In part one , participant randomly assign first group , receive experimental Ebola DNA vaccine , second group , receive experimental Marburg DNA vaccine . In part two , third group receive Ebola Marburg vaccine , one shot arm . One fifth participant group control receive placebo injection . All vaccine placebo deliver via intramuscular injection three time point : study entry , 4 week , 8 week . Participants complete study assessment 12 point time : baseline Weeks 2 , 4 , 6 , 8 , 10 , 12 , 24 , 32 , 52 , 78 , 104 . At assessment , change health medication record blood drawn . Participants also complete diary card daily 5 day receive injection . In , record temperature skin change injection site .</detailed_description>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever , Ebola</mesh_term>
	<mesh_term>Marburg Virus Disease</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Available clinical followup Week 104 Willing photo take identification purpose Willing take home enrollment visit allow home visit appointment keep Completes Assessment Understanding ( AoU ) prior enrollment answer 9 10 question least 3 attempt In good general health without clinically significant medical history Has physical examination laboratory result without clinically significant finding within 28 day prior enrollment Female participant reproductive potential must negative result human choriogonadotropin ( βHCG ) pregnancy test Female participant must either incapable become pregnant agree take appropriate precaution pregnancy occur first 24 week study Pregnant , breastfeeding , plan become pregnant first 24 week enrollment History Ebola Marburg virus exposure Occupational health risk exposure Ebola Marburg virus know higher general population Has receive follow substance : Investigational Ebola Marburg vaccine prior clinical trial Blood product within 120 day prior HIV screen Immunoglobulin within 60 day prior HIV screen Live attenuate vaccine within 30 day prior initial study vaccine administration Investigational research agent within 30 day prior initial study vaccine administration Medically indicate subunit kill vaccine ( influenza , pneumococcal , allergy treatment antigen injection ) within 14 day study vaccine administration Current antituberculosis prophylaxis therapy Immunosuppressive medication , cytotoxic medication , inhaled corticosteroid , longacting betaagonists within 12 week enrollment , except follow case : use corticosteroid nasal spray rhinitis , topical corticosteroid acute uncomplicated dermatitis ; short course ( duration 10 day less , single injection ) corticosteroids nonchronic condition ( base investigator clinical judgement ) least 2 week prior enrollment study History serious adverse reaction vaccine anaphylaxis , urticaria ( hive ) , respiratory difficulty , angioedema , abdominal pain Presence idiopathic urticaria within past 2 year History autoimmune disease immunodeficiency History unstable asthma ; asthma require emergent care , urgent care , hospitalization intubation past 2 year ; asthma require use oral parenteral corticosteroid History diabetes mellitus ( type I II ) , exception history gestational diabetes History thyroidectomy thyroid disease require medication within past 12 month History hereditary angioedema ( HAE ) , acquire angioedema ( AAE ) , idiopathic form angioedema History hypertension well control medication blood pressure 145/95 mm Hg enrollment Presence bleeding disorder diagnose doctor ( e.g. , factor deficiency , coagulopathy , platelet disorder require special precaution ) , significant bruise bleed difficulty intramuscular injection blood draw , routine use anticoagulant medication Presence active malignancy , treated malignancy reasonable assurance sustain cure , malignancy likely recur period study History seizure seizure disorder Asplenia , functional asplenia , condition result absence removal spleen Allergic reaction aminoglycoside antibiotic Presence psychiatric condition precludes compliance protocol History psychosis , bipolar disorder , disorder require lithium , suicide plan attempt within 5 year prior enrollment Any medical , psychiatric , social condition , occupational reason , responsibility , judgment investigator , contraindication protocol participation impair subject 's ability give inform consent Evidence syphilis base history , exam , rapid plasma reagin ( RPR ) test result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Vaccine</keyword>
</DOC>